Comparative Pharmacology
Head-to-head clinical analysis: MAXZIDE 25 versus ORETICYL 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXZIDE 25 versus ORETICYL 50.
MAXZIDE-25 vs ORETICYL 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxzide-25 is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, and triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the collecting duct by blocking epithelial sodium channels.
Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing diuresis.
1 tablet (triamterene 37.5 mg/hydrochlorothiazide 25 mg) orally once daily.
Hydrochlorothiazide 50 mg orally once daily in the morning; may increase to 100 mg daily in divided doses.
None Documented
None Documented
Triamterene: 2-4 hours (terminal half-life due to active metabolite hydroxylated triamterene, clinical effect persists 12-16 hours). Hydrochlorothiazide: 5.6-14.8 hours (mean 8.5 hours).
Terminal elimination half-life: 6–15 hours (mean 10 hours), prolonged in renal impairment (up to 24–30 hours) and elderly.
Renal: triamterene 80-85% (as metabolites, 5-10% unchanged), hydrochlorothiazide ≥95% unchanged via tubular secretion; biliary/fecal: minimal (<5% each).
Renal: ~95% (50% as unchanged drug, remainder as inactive metabolites); Biliary/fecal: <5%.
Category C
Category C
Diuretic Combination
Diuretic Combination